Aml Habas

Aml Habas

Auto-generated profile, based on publicly available information

Aml Habas

Tripoli Pediatric Hospital, Open Libyan University, Tripoli, Libya

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2025 in Blood Pressure
Verified
Journal Article
Closed access
EHElmukhtar Habas
Elmukhtar Habas
ARAmnna Rayani
Amnna Rayani
AHAml Habas
Aml Habas
KFKalifa Farfar
Kalifa Farfar
EHEshrak Habas
Eshrak Habas
GAGamal Alfitori
Gamal Alfitori
BackgroundIntradialytic hypotension (IDH) is the most prevalent complication during hemodialysis (HD) sessions, affecting 10% to 12% of patients. It is linked with temporary ischemic stress in vital organs, increasing patient mortality. Various definitions of IDH have been proposed, and a strong correlation has been found between patient outcomes and the absolute lowest systolic blood pressure. The most probable underlying pathophysiology of IDH involves a reduced effective blood volume and decreased plasma tonicity. Optimizing the dialysis prescription and interventions during and after the dialysis session is sometimes effective for reducing IDH risk.Aim and MethodThis review discusses the pathophysiology, prevention, and therapy of IDH updates. To achieve this aim, Scopus, EMBASE, PubMed, Google, and Google Scholar were searched for articles published in the last two decades using phrases and keywords.ConclusionIntradialytic pathophysiology is ambiguous and unclear. The evidence for the effectiveness of the known therapies and maneuvers is limited. Ideally, IDH prevention should be the target; however, IDH management is sometimes needed. Different obstacles require further clinical research.

26 July 2024 in Blood Pressure
Verified
Journal Article
Open access
EHElmukhtar Habas
Elmukhtar Habas
AEAlmehdi Errayes
Almehdi Errayes
EHEshrak Habas
Eshrak Habas
GAGamal Alfitori
Gamal Alfitori
AHAla Habas
Ala Habas
AEAbdul-Naser Elzouki
Abdul-Naser Elzouki
In the in-clinic blood pressure (BP) recording setting, a sizable number of individuals with normal BP and approximately 30% of patients with chronic renal disease (CKD) exhibit elevated outpatient BP records. These individuals are known as masked hypertension (MHTN), and when they are on antihypertensive medications, but their BP is not controlled, they are called masked uncontrolled hypertension (MUHTN). The masked phenomenon (MP) (MHTN and MUHTN) increases susceptibility to end-organ damage (a two-fold greater risk for cardiovascular events and kidney dysfunction). The potential extension of the observed benefits of MP therapy, including a reduction in end-organ damage, remains questionable. This review aims to study the diagnostic methodology, epidemiology, pathophysiology, and significance of MP management in end-organs, especially the kidneys, cardiovascular system, and outcomes. To achieve the purposes of this non-systematic comprehensive review, PubMed, Google, and Google Scholar were searched using keywords, texts, and phrases such as masked phenomenon, CKD and HTN, HTN types, HTN definition, CKD progression, masked HTN, MHTN, masked uncontrolled HTN, CKD onset, and cardiovascular system and MHTN. We restricted the search process to the last ten years to search for the latest updates. MHTN is a variant of HTN that can be missed if medical professionals are unaware of it. Early detection by ambulatory or home BP recording in susceptible individuals reduces end-organ damage and progresses to sustained HTN. Adherence to the available recommendations when dealing with masked phenomena is justifiable; however, further studies and recommendation updates are required.

2 July 2025 in Turkish Journal of Nephrology
Verified
Journal Article
Open access
EHElmukhtar Habas
Elmukhtar Habas
AHAla Habas
Ala Habas
AEAlmehdi Errayes
Almehdi Errayes
EHEshrak Habas
Eshrak Habas
KFKalifa Farfar
Kalifa Farfar
ARAmnna Rayani
Amnna Rayani
Intradialytic hypertension,ID-HTN,HTN,dialysis-induced HTN,hemodialysis

19 February 2025 in Ukrainian Journal of Nephrology and Dialysis
Verified
Journal Article
Open access
PDF file
EHElmukhtar Habas
Elmukhtar Habas
ARAmnna Rayani
Amnna Rayani
AHAml Habas
Aml Habas
KFKalifa Farfar
Kalifa Farfar
EHEshrak Habas
Eshrak Habas
GAGamal Alfitori
Gamal Alfitori
Chronic kidney disease (CKD) and end-stage kidney disease (ESKD) are common complications of diabetes. Proteinuria is an early indicator of glomerular basement membrane damage caused by diabetes, leading to diabetic kidney disease (DKD). Edema, hypoproteinemia, and proteinuria are common characteristics of DKD. Blood sugar and blood pressure control, along with early detection, are the primary strategies for preventing DKD and slowing its progression. This review examines and updates the epidemiology, pathogenesis, and prevention of DKD. Various keywords and phrases are used to search Google, EMBASE, PubMed, Scopus, and Google Scholar for the most recent articles published from January 2023 to December 2024. Despite advancements in understanding DKD pathogenesis and the development of novel therapies, the disease remains highly prevalent with poor outcomes. The pathophysiology is still not fully understood, leading to gaps in prevention and treatment strategies. Therefore, this review aims to explore these gaps and propose potential new therapies and future research directions.

13 June 2025 in Ukrainian Journal of Nephrology and Dialysis
Verified
Journal Article
Open access
PDF file
EHElmukhtar Habas
Elmukhtar Habas
ARAmnna Rayani
Amnna Rayani
AHAml Habas
Aml Habas
GAGamal Afitori
Gamal Afitori
AHAla Habas
Ala Habas
AEAbdul-Naser Elzouki
Abdul-Naser Elzouki
Anemia following kidney transplantation (KTx) is a prevalent complication that adversely affects allograft function, graft survival, and patient survival. Its etiology is multifactorial, encompassing general causes of anemia and KTx-specific factors, such as immunosuppression and reduced erythropoietin production. Management primarily involves iron supplementation and erythropoiesis-stimulating agents (ESAs); however, specific guidelines for post-KTx anemia are lacking, and the optimal methods for treating iron deficiency in KTx recipients remain undefined. Emerging evidence suggests that sodium-glucose cotransporter-2 inhibitors may improve hemoglobin and hematocrit levels in patients with chronic kidney disease and KTx recipients. To review recent advances in the pathogenesis, epidemiology, treatment, and outcomes of post-KTx anemia, we conducted a literature search using PubMed, Google Scholar, and Google, with keywords including "anemia in kidney transplantation," "anemia etiology in KTx recipients," "iron deficiency in renal transplantation," and "short- and long-term effects of anemia in KTx recipients." This review synthesizes evidence indicating that effective management of post-KTx anemia, through ESAs and supplementation of erythropoiesis essentials (iron, folate, vitamin B12), is safe and may confer renoprotective benefits. Targeted anemia correction enhances quality of life, reduces mortality, improves transplanted kidney function, and lowers the risk of graft rejection, underscoring the need for standardized treatment protocols.